Articles

Gum disease could be associated with…dementia?

Study uncovers an association between periodontal disease and dementia
Written byDDNews Staff
| 3 min read

MINNEAPOLIS - Periodontal disease — especially the irreversible kind that causes tooth loss — could be associated with mild cognitive impairment and dementia 20 years later, according to a study published in today’s online issue of Neurology, the medical journal of the American Academy of Neurology.

“We looked at people’s dental health over a 20-year period and found that people with the most severe gum disease at the start of our study had about twice the risk for mild cognitive impairment or dementia by the end,” said study author Ryan T. Demmer, Ph.D., M.P.H., of the University of Minnesota School of Public Health. “However, the good news was that people with minimal tooth loss and mild gum disease were no more likely to develop thinking problems or dementia than people with no dental problems.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Abstract illustration of colorful spectral emission peaks.
As flow cytometry panels grow larger and more complex, thoughtful panel design has become critical for experimental success.
A scientist in a white lab coat looking into a microscope in a brightly lit modern laboratory.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.